Month: March 2020

COVID-19 Impact on Cell and Gene Therapy Manufacturing Market

With close to half-million infections and the economy showing signs of the 2008 financial crisis, COVID-19 has impacted several industries. Government institutes and industry players have announced various steps to deal with the ongoing situation. In this article, we will highlight the developments in the cell and gene therapy manufacturing industry amid the ongoing COVID-19

Continuous Manufacturing: Solution to Pharmaceutical Manufacturing Industry’s COVID-19 Concerns

The ongoing COVID-19 crisis has put the pharmaceutical manufacturing supply chain under close scrutiny. The overdependence of the US on China and India to meet its API demand has been the talk of the town. However, with the number of infected cases in the US surpassing that of China, the focus has shifted from discussing

COVID-19 Impact on Gene Therapy Market

In a recent press release, bluebird bio, one of the leading gene therapy developers, announced that COVID-19 has delayed the EU launch and US filing of the company’s gene therapy candidate Zynteglo (LentiGlobin). The company now expects to dose the first commercial patient with Zynteglo in Germany in the second half of 2020. Earlier, the company had

Contraband in the Clinical Trials -A saga of the great apes, who went on to ban the nature

To err is human, to rectify divine, this irony perhaps holds truer for cannabis than any other domain. After using cannabis in multiple forms for at least 10,000 years, a series of events, including spread of misinformation, anti-Mexican sentiment and fear led to the ban of nature a.k.a. cannabis. The US implemented Marijuana Tax Act

Immuno-Oncology Biomarker: Benchmarking Big Pharma Activity

Over the past few years, therapeutic advancements in conventional treatment paradigms have led to an increase in survival among cancer patients. Recent developments in the field of immuno-oncology, such as the introduction of several cancer vaccines, adoptive T-cell therapies, and checkpoint inhibition therapies, have demonstrated significant potential, and some of the aforementioned therapies have already